- Home
- PSFE vs PHVS Comparison
PSFE vs PHVS Comparison
Compare PSFE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- PHVS
- Stock Information
- Founded
- PSFE 1996
- PHVS 2015
- Country
- PSFE United Kingdom
- PHVS Netherlands
- Employees
- PSFE N/A
- PHVS N/A
- Industry
- PSFE Business Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- PSFE Consumer Discretionary
- PHVS Health Care
- Exchange
- PSFE Nasdaq
- PHVS Nasdaq
- Market Cap
- PSFE 1.1B
- PHVS 1.0B
- IPO Year
- PSFE N/A
- PHVS 2021
- Fundamental
- Price
- PSFE $18.34
- PHVS $19.14
- Analyst Decision
- PSFE Hold
- PHVS Strong Buy
- Analyst Count
- PSFE 5
- PHVS 5
- Target Price
- PSFE $19.40
- PHVS $40.60
- AVG Volume (30 Days)
- PSFE 271.0K
- PHVS 46.7K
- Earning Date
- PSFE 03-06-2025
- PHVS 11-13-2024
- Dividend Yield
- PSFE N/A
- PHVS N/A
- EPS Growth
- PSFE N/A
- PHVS N/A
- EPS
- PSFE N/A
- PHVS N/A
- Revenue
- PSFE $1,699,306,000.00
- PHVS N/A
- Revenue This Year
- PSFE $9.73
- PHVS N/A
- Revenue Next Year
- PSFE $7.00
- PHVS N/A
- P/E Ratio
- PSFE N/A
- PHVS N/A
- Revenue Growth
- PSFE 8.22
- PHVS N/A
- 52 Week Low
- PSFE $11.94
- PHVS $15.21
- 52 Week High
- PSFE $26.25
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- PSFE 54.97
- PHVS 55.68
- Support Level
- PSFE $17.92
- PHVS $15.21
- Resistance Level
- PSFE $18.31
- PHVS $19.59
- Average True Range (ATR)
- PSFE 0.54
- PHVS 1.42
- MACD
- PSFE 0.21
- PHVS 0.14
- Stochastic Oscillator
- PSFE 94.84
- PHVS 93.82
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet, and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.